SCHEMBL5756798

SCHEMBL5756798

COc1ccccc1CCNC(=O)c1ccc(C)n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.56
MAPT P10636 5/20 0.48
LMNA P02545 3/20 0.48
TSHR P16473 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 1/20 0.48
TP53 P04637 4/20 0.47
POLB P06746 3/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HPGD P15428 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
MTNR1A P48039 1/20 0.44
MTNR1B P49286 1/20 0.44
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5757528 0.91 ELANE (0.63) ELANEMAPTLMNATSHRSMN1; SMN2
SCHEMBL5930799 0.88 ELANE (0.59) ELANELMNASMN1; SMN2POLBNPC1
SCHEMBL5757981 0.87 ELANE (0.61) ELANEMAPTLMNASMN1; SMN2TP53
SCHEMBL5758927 0.87 ELANE (0.58) ELANEMAPTTP53POLBHPGD
SCHEMBL5442982 0.86 MAPT (0.47) MAPTLMNATSHRSMN1; SMN2HTT
SCHEMBL5754315 0.85 ELANE (0.61) ELANEMAPTLMNATSHRSMN1; SMN2
SCHEMBL5757245 0.85 ELANE (0.65) ELANELMNASMN1; SMN2POLBNPC1
SCHEMBL5758208 0.85 MAPT (0.44) ELANEMAPTSMN1; SMN2TP53POLB
SCHEMBL5759088 0.85 ELANE (0.64) ELANESMN1; SMN2POLBHPGDRXFP1
SCHEMBL5758364 0.84 ELANE (0.62) ELANEMAPTLMNATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed
CN-1711243-A 2-pyridone derivatives as inhibitors of neutrophil elastase ASTRAZENECA AB (SE) 2005-12-21 CN disclosed
EP-1562902-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE AstraZeneca AB (SE) 2005-08-17 EP disclosed
WO-2004043924-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885MAPT 1847/4885LMNA 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.